Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / IDRA - Idera announces patent coverage for tilsotolimod through September 2037

IDRA - Idera announces patent coverage for tilsotolimod through September 2037

Idera Pharmaceuticals Inc.
Idera Pharmaceuticals (IDRA) receives patent and is allowed application entitled 'Immune Modulation with TLR9 Agonists for Cancer Treatment' for investigational therapy tilsotolimod.The patents and the allowed application provide exclusivity for certain uses of tilsotolimod through September 2037.“The CRC patent and the soon-to-issue HNSCC patent fortify our ‘beyond melanoma’ strategy for tilsotolimod, which currently includes ongoing development in MSS-CRC via our ILLUMINATE-206 trial and in HNSCC via our collaboration with AbbVie,” said Vincent Milano, CEO.Press ReleaseFind more info on tilsotolimod in company presentation.

For further details see:

Idera announces patent coverage for tilsotolimod through September 2037
Stock Information
Company Name: Idera Pharmaceuticals Inc.
Stock Symbol: IDRA
Market: NASDAQ
Website: iderapharma.com
Menu
IDRA IDRA Quote IDRA Short IDRA News IDRA Articles IDRA Message Board
Get IDRA Alerts

News, Short Squeeze, Breakout and More Instantly...